Journal of Diabetes Investigation最新文献

{"title":"Maximum insulin dose in patients admitted to the intensive care units with severe COVID-19 in the “Cross ICU Searchable Information System” study: A multicenter retrospective cohort study","authors":"Emi Ushigome,&nbsp;Dan Imai,&nbsp;Masahide Hamaguchi,&nbsp;Satoru Hashimoto,&nbsp;Michiaki Fukui","doi":"10.1111/jdi.14380","DOIUrl":"10.1111/jdi.14380","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to determine the maximum daily insulin dose (MDI) and associated factors in critically ill patients with coronavirus disease 2019 (COVID-19) receiving insulin therapy, under ventilator and/or extracorporeal membrane oxygenation (ECMO) management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This cross-sectional analysis used the Cross ICU Searchable Information System data from a Japanese multicenter retrospective observational cohort study of critically ill patients with COVID-19 receiving ventilation and/or ECMO, from February 2020 to March 2022. Maximum daily insulin dose was determined, and factors associated with it and maximum daily insulin dose per body weight were assessed using linear regression analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The analysis included 788 patients. Their mean age, glycated hemoglobin level, maximum daily insulin dose, and time from admission to the maximum daily insulin dose were 65.2 ± 13.0 years, 7.0 ± 1.5% (53.0 ± 7.1 mmol/mol), 46.0 ± 43.6 U/day, and 7.3 ± 7.0 days, respectively. Male sex (β = 6.902, <i>P</i> = 0.034), body mass index (β = 1.020, <i>P</i> = 0.001), glycated hemoglobin (β = 12.272, <i>P</i> &lt; 0.001), and having renal failure (β = 20.637, <i>P</i> = 0.003) were independent determinants of maximum daily insulin dose. Age (β = 0.004, <i>P</i> = 0.035), glycated hemoglobin (β = 0.154, <i>P</i> &lt; 0.001), and having renal failure (β = 0.282, <i>P</i> = 0.004) were independent determinants of maximum daily insulin dose per body weight.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In patients with COVID-19 on ventilator and/or ECMO management, the maximum daily insulin dose reached after about 1 week of hospitalization was approximately 46.0 U/day. Glycated hemoglobin and renal failure were both associated with the maximum daily insulin dose and maximum daily insulin dose per body weight.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 3","pages":"555-560"},"PeriodicalIF":3.1,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14380","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142805758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Placental expression of GLUT-1, GLUT-3, and GLUT-4 mRNA and transcriptome profiling in pregnant women with diabetes","authors":"Rafal Sibiak,&nbsp;Pawel Gutaj,&nbsp;Urszula Mantaj,&nbsp;Lukasz Adamczak,&nbsp;Malgorzata Blatkiewicz,&nbsp;Marcin Rucinski,&nbsp;Ewa Wender-Ozegowska","doi":"10.1111/jdi.14369","DOIUrl":"10.1111/jdi.14369","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>Placental glucose transport is regulated by glucose transporter proteins (GLUTs). The study aimed to examine placental expression of GLUT-1, GLUT-3, and GLUT-4 mRNA in patients with type 1 diabetes, early gestational diabetes (eGDM), and healthy controls, and to investigate correlations between GLUTs expression and clinical parameters. Additionally, we compared placental transcriptome profiles in recruited subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We recruited 59 pregnant women: 23 with type 1 diabetes, 17 with eGDM, and 19 controls. Patients with diabetes attended follow-up visits at each trimester. Transcriptome studies were performed in 4 patients per subgroup.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean age was similar across all subgroups. eGDM patients had significantly higher BMI and were predominantly obese. We observed a significant 2-fold (<i>P</i> = 0.009) decrease in placental GLUT-3 mRNA expression in the type 1 diabetes and eGDM groups. GLUT-4 mRNA expression was significantly lower in the eGDM group compared to type 1 diabetes (3-fold) and controls (6-fold) (<i>P</i> = 0.007). There was a significant negative correlation between GLUT-3 (<i>R</i> = −0.29) and GLUT-4 (<i>R</i> = −0.27) mRNA expression and neonatal birth weight. GLUT-4 expression was negatively correlated with 1st trimester HbA1c (<i>R</i> = −0.72) and OGTT 120′ (<i>R</i> = −0.82) results in eGDM patients, and 3rd trimester glycemic variability (<i>R</i> = −0.49) in type 1 diabetes. Microarray analysis revealed significant transcriptomic changes, with 45 down-regulated and 365 up-regulated genes in type 1 diabetes, and 21 significant changes in eGDM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Placental samples from patients with diabetes exhibit changes in GLUTs expression, which correlates with neonatal growth and several glycemic parameters. Additionally, multiple changes in transcriptomic profiles are observed in hyperglycemic patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 3","pages":"543-554"},"PeriodicalIF":3.1,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14369","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142798814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volume 15","authors":"","doi":"10.1111/jdi.14374","DOIUrl":"https://doi.org/10.1111/jdi.14374","url":null,"abstract":"&lt;p&gt;50-g Oral glucose challenge test&lt;/p&gt;&lt;p&gt;Problems in screening for gestational diabetes mellitus by measurement of casual blood glucose levels at 24–28 gestational weeks, Tomimoto 1797–1802.&lt;/p&gt;&lt;p&gt;β-Cell dysfunction&lt;/p&gt;&lt;p&gt;Glucose metabolism partially regulates β-cell function through epigenomic changes, Kim 649–655.&lt;/p&gt;&lt;p&gt;β-Cells&lt;/p&gt;&lt;p&gt;Role of β-cell autophagy in β-cell physiology and the development of diabetes, Yasasilka 656–668.&lt;/p&gt;&lt;p&gt;β-Cell mass&lt;/p&gt;&lt;p&gt;Effects of glucokinase haploinsufficiency on the pancreatic β-cell mass and function of long-term high-fat, high-sucrose diet-fed mice, Shigesawa 1732–1742.&lt;/p&gt;&lt;p&gt;Accuracy&lt;/p&gt;&lt;p&gt;Impact of hematocrit levels on the accuracy of specific blood glucose meters: A hospital-based study, Pham 1472–1482.&lt;/p&gt;&lt;p&gt;Acyl-coenzyme A synthetase long-chain family member 4&lt;/p&gt;&lt;p&gt;Tanshinone IIA suppresses ferroptosis to attenuate renal podocyte injury in diabetic nephropathy through the embryonic lethal abnormal visual-like protein 1 and acyl-coenzyme A synthetase long-chain family member 4 signaling pathway, Zhu 1003–1016.&lt;/p&gt;&lt;p&gt;Adherence&lt;/p&gt;&lt;p&gt;Modification effect of receipt of diabetes care on the association between COVID-19 infection and HbA1c level during the first year of the coronavirus pandemic using a nationwide population-based database, Okada 953–963.&lt;/p&gt;&lt;p&gt;Prevalence of adherence to oral antidiabetic drugs in patients with type 2 diabetes: A systematic review and meta-analysis, Boonpattharatthiti 1614–1625.&lt;/p&gt;&lt;p&gt;Aging&lt;/p&gt;&lt;p&gt;Association of biomarkers and Barthel Index with occurrence of age-related adverse health outcomes in individuals with diabetes, Umamoto 1675–1683.&lt;/p&gt;&lt;p&gt;Alcohol drinking&lt;/p&gt;&lt;p&gt;The association between alcohol drinking and glycemic management among people with type 2 diabetes in China, Ye 237–244.&lt;/p&gt;&lt;p&gt;Aldehyde dehydrogenase 2&lt;/p&gt;&lt;p&gt;Mitochondrial ALDH2 improves β-cell survival and function against doxorubicin-induced apoptosis by targeting CK2 signaling, Karunakaran 684–692.&lt;/p&gt;&lt;p&gt;Algorithm&lt;/p&gt;&lt;p&gt;A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes—2nd edition (English version), Bouchi 1326–1342.&lt;/p&gt;&lt;p&gt;Alzheimer's disease-like complications of DM&lt;/p&gt;&lt;p&gt;Calpeptin improves the cognitive function in Alzheimer's disease-like complications of diabetes mellitus rats by regulating TXNIP/NLRP3 inflammasome, Qiao 1365–1376.&lt;/p&gt;&lt;p&gt;Angiopoietin-like 4&lt;/p&gt;&lt;p&gt;Angiopoietin-like 4 is a potential biomarker for diabetic kidney disease in type 2 diabetes patients, Wang 1763–1772.&lt;/p&gt;&lt;p&gt;Antidiabetic drugs&lt;/p&gt;&lt;p&gt;Cancer biology in diabetes update: Focusing on antidiabetic drugs, Kawakita 525–540.&lt;/p&gt;&lt;p&gt;Pancreatic beta-cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes, Moon 669–683.&lt;/p&gt;&lt;p&gt;Anti-inflammatory activity&lt;/p&gt;&lt;p&gt;High-density lipoprotein in diabetes: Structural and functional relevance, Lui 805–816.&lt;/p&gt;&lt;p&gt;Anti-oxidative activity&lt;/p&gt;&lt;p&gt;High-density lipoprotein in diabete","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1841-1861"},"PeriodicalIF":3.1,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14374","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142762244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"10.1111/jdi.14324","DOIUrl":"https://doi.org/10.1111/jdi.14324","url":null,"abstract":"&lt;p&gt;The publication of invaluable papers in the Journal of Diabetes Investigation depends on the prompt, careful review of submitted manuscripts. We would like to thank the Editorial Board members, the International Editorial Board members, the Assistant Editorial Board members and the following experts for reviewing manuscripts from September 1, 2023 to August 31, 2024.&lt;/p&gt;&lt;p&gt;Mohammed S. Abusamaan&lt;/p&gt;&lt;p&gt;Adegbenga B. Ademolu&lt;/p&gt;&lt;p&gt;Houssein Ahmadi&lt;/p&gt;&lt;p&gt;Zubair Ahmed&lt;/p&gt;&lt;p&gt;Ken-Ichi Aihara&lt;/p&gt;&lt;p&gt;Yoichi Ajiro&lt;/p&gt;&lt;p&gt;Satoru Akazawa&lt;/p&gt;&lt;p&gt;Hamed Akbari&lt;/p&gt;&lt;p&gt;Gulali Aktas&lt;/p&gt;&lt;p&gt;Nurshad Ali&lt;/p&gt;&lt;p&gt;Shigeru Aoki&lt;/p&gt;&lt;p&gt;Tomohisa Aoyama&lt;/p&gt;&lt;p&gt;Keiko Arai&lt;/p&gt;&lt;p&gt;Atsushi Araki&lt;/p&gt;&lt;p&gt;Osamu Arisaka&lt;/p&gt;&lt;p&gt;Shunichiro Asahara&lt;/p&gt;&lt;p&gt;Kenji Ashida&lt;/p&gt;&lt;p&gt;Yoshimasa Aso&lt;/p&gt;&lt;p&gt;Hande Atalay&lt;/p&gt;&lt;p&gt;Ahmad Khusairi Azemi&lt;/p&gt;&lt;p&gt;Kengo Azushima&lt;/p&gt;&lt;p&gt;Masayuki Baba&lt;/p&gt;&lt;p&gt;Asaad Ma Babker&lt;/p&gt;&lt;p&gt;Mohamed F. Balaha&lt;/p&gt;&lt;p&gt;Ryotaro Bouchi&lt;/p&gt;&lt;p&gt;David S. Boyer&lt;/p&gt;&lt;p&gt;Ali Cetin&lt;/p&gt;&lt;p&gt;Chi-Ming Chan&lt;/p&gt;&lt;p&gt;Te-Fu Chan&lt;/p&gt;&lt;p&gt;Min-Cheol Chang&lt;/p&gt;&lt;p&gt;Deqing Chen&lt;/p&gt;&lt;p&gt;Deyan Chen&lt;/p&gt;&lt;p&gt;Harn-Shen Chen&lt;/p&gt;&lt;p&gt;Juncao Chen&lt;/p&gt;&lt;p&gt;Ming-Wei Chen&lt;/p&gt;&lt;p&gt;Yang Ching Chen&lt;/p&gt;&lt;p&gt;Yen-Lin Chen&lt;/p&gt;&lt;p&gt;Yi-Rong Chen&lt;/p&gt;&lt;p&gt;Kenneth Cheng&lt;/p&gt;&lt;p&gt;Kyu Yong Cho&lt;/p&gt;&lt;p&gt;Soo Choi&lt;/p&gt;&lt;p&gt;Chih-Hsun Chu&lt;/p&gt;&lt;p&gt;Daisuke Chujo&lt;/p&gt;&lt;p&gt;Seung Min Chung&lt;/p&gt;&lt;p&gt;Dana Mihaela Ciobanu&lt;/p&gt;&lt;p&gt;Flávia Campos Corgosinho&lt;/p&gt;&lt;p&gt;Andre Luiz Costa&lt;/p&gt;&lt;p&gt;Xiaona Cui&lt;/p&gt;&lt;p&gt;Makoto Daimon&lt;/p&gt;&lt;p&gt;Taura Daisuke&lt;/p&gt;&lt;p&gt;Undurti Das&lt;/p&gt;&lt;p&gt;Takahisa Deguchi&lt;/p&gt;&lt;p&gt;Masashi Demura&lt;/p&gt;&lt;p&gt;Wuquan Deng&lt;/p&gt;&lt;p&gt;Sunil Deshpande&lt;/p&gt;&lt;p&gt;Domenico Di Raimondo&lt;/p&gt;&lt;p&gt;Yu Ding&lt;/p&gt;&lt;p&gt;Kentaro Doi&lt;/p&gt;&lt;p&gt;Jocelyn J. Drinkwater&lt;/p&gt;&lt;p&gt;Joao M. N. Duarte&lt;/p&gt;&lt;p&gt;Tuba Duman&lt;/p&gt;&lt;p&gt;Jun Eguchi&lt;/p&gt;&lt;p&gt;Akira Endo&lt;/p&gt;&lt;p&gt;Kang-Chih Fan&lt;/p&gt;&lt;p&gt;Lei Feng&lt;/p&gt;&lt;p&gt;Gabor Ferneisz&lt;/p&gt;&lt;p&gt;Chia-Po Fu&lt;/p&gt;&lt;p&gt;Toshihito Fujii&lt;/p&gt;&lt;p&gt;Rumi Fujikawa&lt;/p&gt;&lt;p&gt;Junji Fujikura&lt;/p&gt;&lt;p&gt;Shimpei Fujimoto&lt;/p&gt;&lt;p&gt;Shiho Fujisaka&lt;/p&gt;&lt;p&gt;Yoshihito Fujita&lt;/p&gt;&lt;p&gt;Yukihiro Fujita&lt;/p&gt;&lt;p&gt;Yoshio Fujitani&lt;/p&gt;&lt;p&gt;Michiaki Fukui&lt;/p&gt;&lt;p&gt;Masato Furuhashi&lt;/p&gt;&lt;p&gt;Shinya Furukawa&lt;/p&gt;&lt;p&gt;Hiroto Furuta&lt;/p&gt;&lt;p&gt;Yechiel N. Gellman&lt;/p&gt;&lt;p&gt;Stacey Gorniak&lt;/p&gt;&lt;p&gt;Atsushi Goto&lt;/p&gt;&lt;p&gt;Weaam Gouda&lt;/p&gt;&lt;p&gt;Alpesh Goyal&lt;/p&gt;&lt;p&gt;Tanja Groten&lt;/p&gt;&lt;p&gt;Xuejiang Gu&lt;/p&gt;&lt;p&gt;Yunjuan Gu&lt;/p&gt;&lt;p&gt;Keyu Guo&lt;/p&gt;&lt;p&gt;Kyoung Hwa Ha&lt;/p&gt;&lt;p&gt;Masahide Hamaguchi&lt;/p&gt;&lt;p&gt;Akihiro Hamasaki&lt;/p&gt;&lt;p&gt;Toshiaki Hanafusa&lt;/p&gt;&lt;p&gt;Rikinari Hanayama&lt;/p&gt;&lt;p&gt;Shinichi Harashima&lt;/p&gt;&lt;p&gt;Goji Hasegawa&lt;/p&gt;&lt;p&gt;Koshi Hashimoto&lt;/p&gt;&lt;p&gt;Yoshitaka Hashimoto&lt;/p&gt;&lt;p&gt;Nabil A. Hasona&lt;/p&gt;&lt;p&gt;Yuji Hataya&lt;/p&gt;&lt;p&gt;Yoshitaka Hayashi&lt;/p&gt;&lt;p&gt;Yasuaki Hayashino&lt;/p&gt;&lt;p&gt;Sakoda Hideyuki&lt;/p&gt;&lt;p&gt;Shinji Higuchi&lt;/p&gt;&lt;p&gt;Tatsuhito Himeno&lt;/p&gt;&lt;p&gt;Tsutomu Hirano&lt;/p&gt;&lt;p&gt;Satoshi Hirayama&lt;/p&gt;&lt;p&gt;Takahisa Hirose&lt;/p&gt;&lt;p&gt;Inoue Hiroshi&lt;/p&gt;&lt;p&gt;Yushi Hirota&lt;/p&gt;&lt;p&gt;Takanori Honda&lt;/p&gt;&lt;p&gt;Minha Hong&lt;/p&gt;&lt;p&gt;Ruby Hoo&lt;/p&gt;&lt;p&gt;Ichiro Horie&lt;/p&gt;&lt;p&gt;Takeshi Horii&lt;/p&gt;&lt;p&gt;Yukio Horikawa&lt;/p&gt;&lt;p&gt;Masayuki Hosoi&lt;/p&gt;&lt;p&gt;Yi-Ting Hsieh&lt;/p&gt;&lt;p&gt;Paul Hsu&lt;/p&gt;&lt;p&gt;Cheng Hu&lt;/p&gt;&lt;p&gt;Haofei Hu&lt;/p&gt;&lt;p&gt;Chia-Luen Huang&lt;/p&gt;&lt;p&gt;Chuiguo Huang&lt;/p&gt;&lt;p&gt;Cn Huang&lt;/p&gt;&lt;p&gt;Yu-Tung Huang&lt;/p&gt;&lt;p&gt;Zhimin Huang&lt;/p&gt;&lt;p&gt;Mikael S Huhtala&lt;/p&gt;&lt;p&gt;Sartaj Hussain&lt;/p&gt;&lt;p&gt;You-Cheol H","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1838-1840"},"PeriodicalIF":3.1,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14324","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142762243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gestational diabetes in early pregnancy is associated with postpartum glucose intolerance: A perspective from the diabetes and pregnancy outcome for mother and baby study in Japan","authors":"Maki Yokoyama,&nbsp;Kei Miyakoshi,&nbsp;Noriyuki Iwama,&nbsp;Hiroshi Yamashita,&nbsp;Ichiro Yasuhi,&nbsp;Maki Kawasaki,&nbsp;Naoko Arata,&nbsp;Shiori Sato,&nbsp;Yuko Imura,&nbsp;Masako Waguri,&nbsp;Haruna Kawaguchi,&nbsp;Naoki Masaoka,&nbsp;Yoshiyuki Nakajima,&nbsp;Yuji Hiramatsu,&nbsp;Takashi Sugiyama,&nbsp;DREAMBee Study Gestational Diabetes Mellitus Group","doi":"10.1111/jdi.14368","DOIUrl":"10.1111/jdi.14368","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To compare perinatal outcomes and postpartum glucose tolerance between women diagnosed with gestational diabetes mellitus (GDM) before 20 weeks of gestation (EGDM) and those diagnosed at or after 24 weeks of gestation (LGDM) in a Japanese population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Data were obtained from a prospective GDM registry. Multivariate analysis was conducted to examine the association between the timing of GDM diagnosis (EGDM vs LGDM) and perinatal outcomes (preterm birth, small for gestational age, large for gestational age, pregnancy-induced hypertension, and neonatal hypoglycemia), as well as postpartum glucose intolerance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1,275 mother-infant pairs were analyzed for perinatal outcomes. Of these, 924 women underwent postpartum testing for glucose intolerance. No significant differences in perinatal outcomes were observed between the EGDM and LGDM groups, except that overweight/obese women with EGDM had 2.5-fold higher rate of preterm birth than those with LGDM. Postpartum glucose intolerance was 1.5 times more likely in the EGDM group than in the LGDM group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Women with EGDM had a significantly higher risk of postpartum glucose intolerance than those with LGDM, despite similar perinatal outcomes between the two groups.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 3","pages":"535-542"},"PeriodicalIF":3.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14368","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes remission in newly diagnosed type 2 diabetes mellitus through short-term continuous subcutaneous insulin infusion intensive therapy combined with low-carbohydrate diet treatment","authors":"Xuemei Huang,&nbsp;Jiajin Jiang,&nbsp;Li Liu,&nbsp;Yuanyuan Lin,&nbsp;Feng Zhang,&nbsp;Xiaoshan Ling,&nbsp;Haitao Wei,&nbsp;Guangjing Huang,&nbsp;Jinqun Ye,&nbsp;Cen Huang,&nbsp;Jianli Huang,&nbsp;Wenfu Tao,&nbsp;Xinyu Zou","doi":"10.1111/jdi.14371","DOIUrl":"10.1111/jdi.14371","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim/Introduction</h3>\u0000 \u0000 <p>To evaluate the therapeutic efficacy short-term continuous subcutaneous insulin infusion (CSII) intensive therapy combined with a low-carbohydrate diet (LCD) for diabetes remission in patients with newly diagnosed type 2 diabetes mellitus.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This study included patients newly diagnosed with type 2 diabetes mellitus, who were randomly divided into two groups: conventional (conventional CSII + traditional lifestyle guidance); and intensive (intensive CSII + LCD lifestyle guidance). CSII was used for blood glucose control, with continuous glucose monitoring (CGM) used to monitor blood glucose levels. The primary outcome measure was hemoglobin A1c (HbA1c) level; secondary outcomes included body weight, body mass index (BMI), waist circumference, glycemic control, and biochemical indices.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The time in range (TIR) in the intensive treatment group was greater than that in the conventional treatment group (<i>P</i> &lt; 0.05). There was no significant difference in the incidence of hypoglycemia between the two groups (<i>P</i> &gt; 0.05). Compared with the conventional treatment group, diabetes remission rates were significantly greater in the intensive treatment group (<i>P</i> &lt; 0.05). In the intensive treatment group, fasting plasma glucose (FPG), HbA1c, Homeostasis Model assessment of Insulin Resistance (HOMA-IR), triglycerides (TG), low-density lipoprotein cholesterol (LDL-c), and changes in body weight, BMI, visceral fat area (VFA), and subcutaneous fat area (SFA) decreased significantly (<i>P</i> &lt; 0.05). FPG, HOMA-IR, TG, LDL-c, and changes in body weight, BMI, waist circumference, and VFA were significantly correlated with HbA1c levels (<i>P</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The combination of intensive CSII and LCD lifestyle guidance had been improved the remission rate in patients with newly diagnosed type 2 diabetes mellitus.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 3","pages":"426-433"},"PeriodicalIF":3.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14371","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on “Non-classical monocytes frequency and serum vitamin D3 levels are linked to diabetic foot ulcer associated with peripheral artery disease”","authors":"Mostafa Javanian,&nbsp;Mohammad Barary,&nbsp;Soheil Bakhshinasab,&nbsp;Soheil Ebrahimpour","doi":"10.1111/jdi.14356","DOIUrl":"10.1111/jdi.14356","url":null,"abstract":"&lt;p&gt;We read with great interest the article titled “Non-classical Monocyte Frequency and Serum Vitamin D3 Levels are Linked to Diabetic Foot Ulcer Associated with Peripheral Artery Disease,” published in your esteemed journal&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;. The research highlights the reduced frequency of non-classical monocytes and low vitamin D3 levels in patients with diabetic foot ulcers (DFUs) associated with peripheral artery disease (PAD), shedding light on the potential role of these factors in DFU pathogenesis. We commend the authors for this valuable contribution, but we believe several methodological improvements could further enhance the study's impact.&lt;/p&gt;&lt;p&gt;The study's focus on limited laboratory markers may have overlooked other potential indicators. Additional biomarkers, such as calcium, potassium, uric acid, liver function tests, and indices like the systemic immune-inflammation index (SII) and the systemic inflammation response index (SIRI), could provide deeper insights into the inflammatory processes at play in DFU patients&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;. This might help better predict poor outcomes.&lt;/p&gt;&lt;p&gt;Although the Meggitt–Wagner classification provided useful data, it lacks a clear focus on vascular involvement. Other classification systems, such as the PEDIS and SINBAD systems, which evaluate factors like perfusion, depth, infection, and ischemia, could offer a more comprehensive assessment of DFUs and their correlation with PAD&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p&gt;The study did not explore other medications beyond antidiabetic drugs that patients might have been using, nor did it address the impact of conditions like cancer, hematologic disorders, or autoimmune diseases. These factors can influence immune function and thus alter the study outcomes.&lt;/p&gt;&lt;p&gt;Alcohol consumption was not investigated, despite its known role in DFU outcomes. Additionally, categorizing smoking status into non-smokers, former smokers, and current smokers could provide a clearer picture of its impact on DFU development and progression.&lt;/p&gt;&lt;p&gt;Classifying PAD into mild, moderate, and severe categories and comparing the frequency of non-classical monocytes and vitamin D3 levels across these groups would enrich the analysis, offering more nuanced insights into the relationship between PAD severity and immune response.&lt;/p&gt;&lt;p&gt;The relatively small sample size of the study could limit its statistical power, leading to wider margins of error. A larger cohort would increase the robustness of the findings, ensuring better generalizability and precision&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p&gt;In conclusion, while this study makes a significant contribution to our understanding of the relationship between non-classical monocytes, vitamin D3, and DFUs associated with PAD, addressing the outlined limitations would strengthen the findings and their implications. We believe that future studies incorporating these factors could further advance research in this critical area.&lt;/p&gt;&lt;p&gt;The aut","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 2","pages":"350-351"},"PeriodicalIF":3.1,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142724424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in prescribing sodium-glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular-renal disease in South Korea, 2015–2021","authors":"Kyoung Hwa Ha,&nbsp;Soyoung Shin,&nbsp;EunJi Na,&nbsp;Dae Jung Kim","doi":"10.1111/jdi.14363","DOIUrl":"10.1111/jdi.14363","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study evaluates shifts in oral glucose-lowering drug prescription patterns and the adoption of sodium-glucose cotransporter 2 inhibitors (SGLT2is) in South Korea.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional and retrospective cohort analysis of the Korean National Health Insurance database (2015–2021) assessed the prescription patterns of oral glucose-lowering drugs by therapy level, SGLT2i prescriptions by cardiovascular-renal disease (CVRD) status, and the mean duration for SGLT2i therapy initiation and intensification.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From 2015 to 2021, the number of individuals prescribed oral glucose-lowering drugs across all regimen levels increased. However, the proportion of individuals receiving monotherapy or dual combination therapy decreased by 9.2 percentage points, whereas the proportion prescribed triple or more combination therapy increased. SGLT2i prescriptions increased from 2.5% in 2015 to 13.9% in 2021, marking an 11.4 percentage point growth. This trend was consistent among individuals with and without CVRD, with the most significant increase observed in individuals with heart failure—from 2.2% in 2015 to 16.6%. The mean time to SGLT2i initiation post-diagnosis was shortened from 249 days in 2015 to 158 days in 2019.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The adoption of SGLT2i therapy was on the rise, especially among individuals with heart failure, accompanied by a notable decrease in time to treatment initiation. Despite these positive trends, the overall use of SGLT2i among individuals with CVRD remained limited.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 2","pages":"215-224"},"PeriodicalIF":3.1,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes","authors":"Koichi Asahi,&nbsp;Tsuneo Konta,&nbsp;Kouichi Tamura,&nbsp;Fumitaka Tanaka,&nbsp;Akira Fukui,&nbsp;Yusuke Nakamura,&nbsp;Junichi Hirose,&nbsp;Kenichi Ohara,&nbsp;Yoko Shijoh,&nbsp;Matthew Carter,&nbsp;Kimberley Meredith,&nbsp;James Harris,&nbsp;Örjan Åkerborg,&nbsp;Naoki Kashihara,&nbsp;Takashi Yokoo","doi":"10.1111/jdi.14293","DOIUrl":"10.1111/jdi.14293","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>This analysis seeks to evaluate the cost-effectiveness of urine albumin-to-creatinine ratio testing compared with urine protein-creatinine ratio testing and no urine testing for the identification of kidney damage in individuals with type 2 diabetes who have, or are at risk of, chronic kidney disease in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A health-economic model estimated the clinical and economic consequences of different tests to evaluate kidney damage in line with Japanese guidelines, taking a Japanese healthcare perspective. Differences in the diagnostic performance of tests were considered by the integration of real-world Japanese data. Outcomes were considered over a lifetime horizon, and included costs, prevented dialyses, life years gained, quality-adjusted life years, and incremental cost-effectiveness ratios.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Repeated urine albumin-to-creatinine ratio testing was found to be cost-effective compared with both urine protein-creatinine ratio testing and no urine testing, yielding incremental cost-effectiveness ratios of ¥2,652,693 and ¥2,460,453, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Repeated urine albumin-to-creatinine ratio testing is cost-effective compared with urine protein-creatinine ratio testing and no urine testing in Japanese individuals with type 2 diabetes, supporting existing clinical evidence that albumin-to-creatinine ratio testing should be used more widely, particularly compared with other urine tests such as urine protein-creatinine ratio testing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 1","pages":"108-119"},"PeriodicalIF":3.1,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between severity of diabetic complications and risk of cancer in middle-aged patients with type 2 diabetes","authors":"Yao-Hsien Tseng,&nbsp;Yu-Tse Tsan,&nbsp;Pau-Chung Chen","doi":"10.1111/jdi.14364","DOIUrl":"10.1111/jdi.14364","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Hyperglycemia was found to be associated with an increased risk of cancer in a general population cohort. However, it remains to be established whether the severity of diabetic complications is associated with cancer risk in patients with diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We used the National Health Insurance Research Database from 2000 through 2013, including those with newly diagnosed diabetic patients (<i>n</i> = 616,742). We collected all vascular and metabolic complications to develop an adapted diabetic complication severity index (aDCSI), ranging from 0 to 13 annually, as proxies of the severity of diabetic complications and performed follow-up from the onset of diabetes until incident cancer, death, or the study end.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Within the mean follow-up period of 9 years, the rates of cancer incidence per 100,000 person-years were 815.2 vs 482.0 and 611.1 vs 358.9 for the top vs bottom quartiles, respectively, of aDCSI in men and women (adjusted HRs 1.17 (95% CI 1.10–1.25) and 1.20 (95% CI 1.10–1.30), respectively). The risk of cancer was 1.7- to 1.9-fold for the top vs bottom quartiles of aDCSI in diabetic onset age of 40–44 (HRs 1.74 (95% CI, 1.39–2.18) in men and HRs 1.93 (95% CI, 1.39–2.66) in women). However, among patients with diabetic onset age of 60–64, the associations between the severity of diabetic complications and cancer risk were attenuated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients with higher severity of diabetic complications have an increased risk of cancer compared to those with the lowest severity, particularly for those with earlier onset and greater severity of diabetic complications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 1","pages":"16-24"},"PeriodicalIF":3.1,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142685530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}